Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
The independent financial analyst theScreener just lowered the general evaluation of CANTEL MEDICAL CORP. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date June 4, 2021, the closing price was USD 80.37 and its target price was estimated at USD 63.46.
A director at Cantel Medical Corp bought 2,500 shares at 38.826USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...
II-VI Incorporated (IIVI:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 19.7x Uniform P/E, implying bearish expectations for the firm. Although management may be concerned about guidance, 200G and 400G transceiver sales, and silicon carbide product demand, market expectations are too bearish, and long-term equity upside is warranted. Specifically, management may lack confidence in their ability to meet Q1 EPS guidance and 2022 revenue forecasts for the semiconductor capital equipment business. Additionally, they may be exaggerating their pric...
Entegris, Inc. (ENTG:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 32.9x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about the resilience of their business model, sequential growth, and margins in the Advanced Materials Handling (AMH) segment. Specifically, management may have concerns about the resilience of their business model, the margin mix impact in their SCEM business, and the significance of non-core intellectual property (IP) sales. Also, they may be overstating r...
ON Semiconductor Corporation (ON:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 20.0x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may have concerns about their gross margins, cost reduction initiatives, and their East Fishkill foundry ramp-up. Specifically, management may lack confidence in their ability to improve gross margin, execute their cost reduction initiatives, and improve capacity. Furthermore, they may be exaggerating the sustainability of semiconductor demand, the effic...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.